Inhibitors of HMG-CoA Reductase: Current and Future Prospects
Narender Singh1, Joaquín Tamariz, Germán Chamorro
1Torrey Pines Institute for Molecular Studies, Port St. Lucie, Florida 34987, USA.
Abstract:
High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacogenomics: Identification of New Drug Targets
Inhibitors of Viral Protein Synthesis
Feedback Inhibition
Enzyme Inhibition
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
